CARsgen Therapeutics is a pioneering biopharmaceutical brand with operations in China and the U. S. They specialize in developing groundbreaking CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors.

With an integrated cell therapy platform, CARsgen excels in target discovery, antibody development, clinical trials, and commercial-scale manufacturing. Their commitment to innovation has allowed them to establish a robust product pipeline with global rights. One of CARsgen's leading candidates is zevorcabtagene autoleucel, also known as zevor-cel or CT053.

This autologous B-cell maturation antigen (BCMA) CAR T-cell product shows promising results in treating relapsed/refractory multiple myeloma (R/R MM). Additionally, CARsgen is developing CT041, an autologous CAR T-cell product candidate targeting the protein CLDN18. 2.

This therapy aims to address the challenges posed by gastric cancer (GC), pancreatic cancer (PC), and other solid tumors. CARsgen Therapeutics blends cutting-edge technology, expertise, and a drive for improving patients' lives. With their dedication to advancing CAR T-cell therapies, they are revolutionizing the field of oncology